Malignant hyperthermia in North America: Genetic screening of the three hot spots in the type I ryanodine receptor gene

Yoshitatsu Sei, Nyamkhishig N. Sambuughin, Edward J. Davis, Daniel Sachs, Phil B. Cuenca, Barbara W. Brandom, Timothy J Tautz, Henry Rosenberg, Thomas E. Nelson, Sheila M. Muldoon

Research output: Contribution to journalArticle

48 Scopus citations

Abstract

Background: Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle, manifested as a life-threatening hypermetabolic crisis after exposure to anesthetics. Type 1 ryanodine receptor 1 Is the primary gene responsible for susceptibility to MH as well as central core disease, a congenital myopathy that predisposes susceptibility to MH. More than 40 mutations in the RyR1 gene cluster in three coding regions: the N-terminus, central, and C-terminus regions. However, the frequency of mutations in each region has not been studied in the North American MH-susceptible population. Methods: The authors tested 124 unrelated patients with MH susceptibility for the presence of mutations in the N-terminus (exons 2, 6, 9, 11, 12, and 17), central (exons 39, 40, 44, 45, and 46), and C-terminus (exons 95, 100, 101, and 102) regions. Results: Fourteen mutations have been identified in 29 of 124 MH-susceptible patients (23%). Approximately 70% of the mutations, which include a novel mutation, Ala 2437Val, were in the central region. In 8 patients (28%), mutations were identified in the N-terminus region. Screening the C-terminus region yielded a novel mutation, Leu4824Pro, in a single patient with a diagnosis of central core disease. Conclusions: The detection rate for mutations is only 23% by screening mutations (or exons) listed in the 2002 North American consensus panel. The implications from this study suggest that testing the central region first is currently the most effective screening strategy for the North American population. Screening more exons in the three hot spots may be needed to find an accurate frequency of mutations in the RyR1 gene.

Original languageEnglish (US)
Pages (from-to)824-830
Number of pages7
JournalAnesthesiology
Volume101
Issue number4
DOIs
StatePublished - Oct 2004

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Malignant hyperthermia in North America: Genetic screening of the three hot spots in the type I ryanodine receptor gene'. Together they form a unique fingerprint.

  • Cite this

    Sei, Y., Sambuughin, N. N., Davis, E. J., Sachs, D., Cuenca, P. B., Brandom, B. W., Tautz, T. J., Rosenberg, H., Nelson, T. E., & Muldoon, S. M. (2004). Malignant hyperthermia in North America: Genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology, 101(4), 824-830. https://doi.org/10.1097/00000542-200410000-00005